Mode
Text Size
Log in / Sign up
N/A Completed N=174 Randomized Treatment

Comparison of Oxygenation and Ventilation With a Novel Nasal Mask Versus Standard of Care During Colonoscopy

Colonoscopy · Oxygenation · Ventilation
Source: ClinicalTrials.gov NCT03139448 ↗
Enrolled (actual)
174
Serious AEs
0.0%
Results posted
Feb 2019
Primary outcomePrimary: Time to First Intervention — 10; 19 minutes

Summary

Nasal continuous positive airway pressure (nCPAP) has been shown to effectively relieve upper airway obstruction in patients with OSA as it creates a pneumatic stent in the hypopharynx that reduces obstruction and allows for continuous oxygenation. Nasal ventilation was also proven to be more effective than combined oral-nasal ventilation during induction of general anesthesia in adult subjects. However, it is not clear if nasal mask can be used safely for oxygenation and ventilation in patients undergoing colonoscopy. The SuperNO2VA™ device is a new commercially available nasal mask that provides both nasal CPAP and nasal mask ventilation. The objective of this study is to compare the efficacy of oxygenation and ventilation during colonoscopy using the novel nasal mask, SuperNO2VA™, and standard care with nasal cannula.

Outcome Measures

OutcomeResultp-value
PRIMARY
Time to First Intervention
10; 19
SECONDARY
Number of Subjects Receiving Interventions for Airway Management
46; 14
SECONDARY
Duration of Intervention
19; 12
SECONDARY
Oxygen Saturation Reading- Median
100.0; 100; 98; 100; 99; 100
SECONDARY
Oxygen Saturation- Lowest Reading
99.11; 99.23; 96.22; 99.31; 97.57; 99.39
SECONDARY
Number of Participants With Oxygen Saturation- Reading Below 90%
16; 3
SECONDARY
Tidal Volume (VT)
1032.80; 1011.39; 527.01; 625.31; 533.26; 589.22
SECONDARY
Respiratory Rate (RR)
15.07; 15.36; 15.15; 15.21; 17.77; 16.95
SECONDARY
Minute Ventilation (MV)
14.29; 14.52; 8.41; 9.16; 8.82; 9.62

Eligibility Criteria

Inclusion Criteria

  • Patients 18 years or older
  • BMI of 30-50
  • ASA 1-3 Scheduled for colonoscopy with sedation

Exclusion Criteria

  • Untreated ischemic heart disease
  • Acute and chronic respiratory disorders, including COPD and asthma
  • Emergent procedures
  • Planned use of an invasive airway (ie: supra-glottic device, LMA, etc)
  • Pregnant women
  • Nasal or oral disease resulting in difficulty of either nasal breathing or mouth breathing
  • Patient refusal
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03139448). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search